|
1
|
Balakrishnan M, George R, Sharma A and
Graham DY: Changing trends in stomach cancer throughout the world.
Curr Gastroenterol Rep. 19:362017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kodera Y: The current state of stomach
cancer surgery in the world. Jpn J Clin Oncol. 46:1062–1071. 2016.
View Article : Google Scholar
|
|
3
|
Yako-Suketomo H and Katanoda K: Comparison
of time trends in stomach cancer mortality (1990–2006) in the
world, from the WHO mortality database. Jpn J Clin Oncol.
39:622–623. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yamamoto S: Stomach cancer incidence in
the world. Jpn J Clin Oncol. 31:4712001.PubMed/NCBI
|
|
5
|
Lu J, Huang CM, Zheng CH, Li P, Xie JW,
Wang JB and Lin JX: Analysis on the clinical and pathological
features and prognosis of familial gastric cancer in South China
population: A single-center study of 724 patients. J Oncol.
2012:6412182012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kudou M, Kosuga T, Kubota T, Okamoto K,
Komatsu S, Shoda K, Konishi H, Shiozaki A, Fujiwara H, Arita T, et
al: Value of preoperative PET-CT in the prediction of pathological
stage of gastric cancer. Ann Surg Oncol. 25:1633–1639. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Joo I, Lee JM, Kim JH, Shin CI, Han JK and
Choi BI: Prospective comparison of 3T MRI with diffusion-weighted
imaging and MDCT for the preoperative TNM staging of gastric
cancer. J Magn Reson Imaging. 41:814–821. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Low RN and Gurney J: Diffusion-weighted
MRI (DWI) in the oncology patient: Value of breathhold DWI compared
to unenhanced and gadolinium-enhanced MRI. J Magn Reson Imaging.
25:848–858. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hansen AE, McEvoy F, Engelholm SA, Law I
and Kristensen AT: FDG PET/CT imaging in canine cancer patients.
Vet Radiol Ultrasound. 52:201–206. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cohade C, Osman M, Pannu HK and Wahl RL:
Uptake in supraclavicular area fat (‘USA-Fat’): Description on
18F-FDG PET/CT. J Nucl Med. 44:170–176. 2003.PubMed/NCBI
|
|
11
|
Freitag MT, Radtke JP, Hadaschik BA,
Kopp-Schneider A, Eder M, Kopka K, Haberkorn U, Roethke M,
Schlemmer HP and Afshar-Oromieh A: Comparison of hybrid (68)Ga-PSMA
PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and
bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging.
43:70–83. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shin S, Pak K and Kim SJ, Kim H and Kim
SJ: Pulmonary tumor embolism derived from stomach cancer
observation with serial 18F-FDG PET/CT. Clin Nucl Med.
40:270–272. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Han K, Croke J, Foltz W, Metser U, Xie J,
Shek T, Driscoll B, Ménard C, Vines D, Coolens C, et al: A
prospective study of DWI, DCE-MRI and FDG PET imaging for target
delineation in brachytherapy for cervical cancer. Radiother Oncol.
120:519–525. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang TT, Qian XP and Liu BR: Survivin:
Potential role in diagnosis, prognosis and targeted therapy of
gastric cancer. World J Gastroenterol. 13:2784–2790. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jambor I, Kuisma A, Ramadan S, Huovinen R,
Sandell M, Kajander S, Kemppainen J, Kauppila E, Auren J, Merisaari
H, et al: Prospective evaluation of planar bone scintigraphy,
SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI,
including DWI, for the detection of bone metastases in high risk
breast and prostate cancer patients: SKELETA clinical trial. Acta
Oncol. 55:59–67. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ehman EC, Johnson GB, Villanueva-Meyer JE,
Cha S, Leynes AP, Larson PEZ and Hope TA: PET/MRI: Where might it
replace PET/CT? J Magn Reson Imaging. 46:1247–1262. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mhlanga JC, Chirindel A, Lodge MA, Wahl RL
and Subramaniam RM: Quantitative PET/CT in clinical practice:
Assessing the agreement of PET tumor indices using different
clinical reading platforms. Nucl Med Commun. 39:154–160.
2018.PubMed/NCBI
|
|
18
|
Cazzato RL, Garnon J, Shaygi B, Koch G,
Tsoumakidou G, Caudrelier J, Addeo P, Bachellier P, Namer IJ and
Gangi A: PET/CT-guided interventions: Indications, advantages,
disadvantages and the state of the art. Minim Invasive Ther Allied
Technol. 27:27–32. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stecco A, Buemi F, Cassarà A, Matheoud R,
Sacchetti GM, Arnulfo A, Brambilla M and Carriero A: Comparison of
retrospective PET and MRI-DWI (PET/MRI-DWI) image fusion with
PET/CT and MRI-DWI in detection of cervical and endometrial cancer
lymph node metastases. Radiol Med (Torino). 121:537–545. 2016.
View Article : Google Scholar
|
|
20
|
Catalano OA, Daye D, Signore A, Iannace C,
Vangel M, Luongo A, Catalano M, Filomena M, Mansi L, Soricelli A,
et al: Staging performance of whole-body DWI, PET/CT and PET/MRI in
invasive ductal carcinoma of the breast. Int J Oncol. 51:281–288.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gaeta CM, Vercher-Conejero JL, Sher AC,
Kohan A, Rubbert C and Avril N: Recurrent and metastatic breast
cancer PET, PET/CT, PET/MRI: FDG and new biomarkers. Q J Nucl Med
Mol Imaging. 57:352–366. 2013.PubMed/NCBI
|
